Wednesday, May 07, 2025 1:03:43 PM
Roblok, I had a few more shares put to me today from some June $7 puts that I sold quite a while back. Interestingly, the last time I had shares put to me, the stock price actually went up nicely for a few weeks following. Maybe again? Who knows.
I'm looking down the road to the next few quarters. I suspect that the CCO is working hard to earn all those contractual bonuses that require beating current 2025 total guidance. He didn't sign that contract just for a paycheck, he's playing for a much bigger payday which requires greater success for Iovance.
As I mentioned on another board: Who needs a crystal ball...
Here's a few job openings that should clue us in to how confident this company is about the next prospects for market expansion:
0045-GLOBAL COMMERCIAL
Commercial Lead, Head of France
Commercial Lead, Head of Germany
Commercial Lead, Head of UK
Ex-US Case Manager [Switzerland, UK, Netherlands]
https://www.iovance.com/current-opportunities/
GL to IOVA longs.
I'm looking down the road to the next few quarters. I suspect that the CCO is working hard to earn all those contractual bonuses that require beating current 2025 total guidance. He didn't sign that contract just for a paycheck, he's playing for a much bigger payday which requires greater success for Iovance.
As I mentioned on another board: Who needs a crystal ball...
Here's a few job openings that should clue us in to how confident this company is about the next prospects for market expansion:
0045-GLOBAL COMMERCIAL
Commercial Lead, Head of France
Commercial Lead, Head of Germany
Commercial Lead, Head of UK
Ex-US Case Manager [Switzerland, UK, Netherlands]
https://www.iovance.com/current-opportunities/
GL to IOVA longs.
Recent IOVA News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/17/2026 09:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:01:25 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (US) • 04/01/2026 12:49:00 AM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (Canada) • 03/24/2026 02:00:00 PM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (US) • 03/24/2026 02:00:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:12 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:01:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:01:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:00:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 10:00:18 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 02/26/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/24/2026 02:35:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 01:00:40 PM
- Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
